Allergan, Inc. v. Lupin Ltd. et al, No. 2:11-cv-00530 (E.D. Tex. Aug. 21, 2013)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court are Plaintiff Allergan Sales, LLC’s Opening Claim Construction Brief (Dkt. No. 107), Defendants’ response (Dkt. No. 112), and Plaintiff’s reply (Dkt. No. 116), concerning U.S. Patent Nos. 8,008,338 (“the ‘338 patent), 8,207,215 (“the ‘215 patent”); and 8,377,982 (“the ‘982 patent”). The Court held a hearing on August 6, 2013. 2 I. BACKGROUND Plaintiff alleges infringement of the ‘338, ‘215, and ‘982 patents by Defendants through their manufacture and sale of generic versions of Plaintiff’s Acular LS® product.